Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
Using significant factors from multivariate analyses, based on 20 putative markers from a consecutive series of 1198 Sheffield Lymphoma Group patients, risk-adjusted prognostic models had been previously derived for Hodgkin's disease (HD) (using age, albumin and lymphocyte count) and non-Hodgkin's lymphoma (NHL) grade II (based on albumin, age, erythrocyte sedimentation rate, lactate dehydrogenase and stage). Data from 6728 patients on the British National Lymphoma Investigation database were used for validation: thus the models were applied to 4411 patients with HD and 2317 patients with NHL grade II. Survival curves derived from these validation groups confirmed our risk models.
Low
Su E
SE
YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
Horsman
Janet M
JM
Walters
Stephen J
SJ
Hancock
Helen
H
Smith
Paul
P
Linch
David
D
Hancock
Barry W
BW
D000328:Adult; D000367:Age Factors; D015415:Biomarkers / Q000097:blood; D001799:Blood Sedimentation; D006689:Hodgkin Disease / Q000097:blood / Q000276:immunology / Q000401:mortality*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016015:Logistic Models; D018655:Lymphocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000276:immunology / Q000401:mortality*; D008875:Middle Aged; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis; D016019:Survival Analysis
D015415:Biomarkers; D012709:Serum Albumin; D007770:L-Lactate Dehydrogenase